Cardiovascular Risk Management for Type 2 Diabetes

(CVRiD Trial)

Overseen By Jack Reilly

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: American College of Cardiology

Must not be taking: SGLT2i, GLP-1RA

Disqualifiers: Type 1 diabetes, Pregnancy, Hospice, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

750 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This initiative supports a real-world study of practice and physician prescribing patterns and a quality improvement initiative evaluating best practices (including clinical decision support, facilitated referral to cardiometabolic team-based care model, and general educational tools/resources) to im-prove use of guideline-directed therapeutics known to lower cardiovascular risk (CV) in patients with type 2 diabetes (T2D).

Are You a Good Fit for This Trial?

This trial is for adults with type 2 diabetes who have a history of cardiovascular issues like stroke, artery disease, or heart problems. They must not be on certain diabetes medications (SGLT2i or GLP-1RA), have severe liver disease, pancreatitis, cancer, less than a year to live, or be pregnant/breastfeeding.

Inclusion Criteria

I have a history of heart disease, including heart attack or procedures to open my heart's arteries.

I have had artery disease in my legs, including treatments to improve blood flow.

I have had a stroke, TIA, or surgery to open my neck arteries.

Exclusion Criteria

I have a history of medullary thyroid cancer or MEN-2.

You are currently taking part in a study testing a new drug or medical device, except for studies related to COVID-19.

You have had a heart transplant or have plans to get a ventricular assist device.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Education and Decision Support

Participants receive education and decision support to optimize care

9 months

Follow-up

Participants are monitored for new prescriptions of SGLT2i and/or GLP-1RA

9 months

What Are the Treatments Tested in This Trial?

Interventions

• Decision support
• Facilitated referral to a cardiometabolic team-based center

Trial Overview The study tests how decision support tools and referrals to specialized cardiometabolic care can improve the use of treatments that lower heart risk in people with type 2 diabetes. It's about finding best practices in real-world medical settings.

How Is the Trial Designed?

Group I: Education alone Active Control 1 Intervention

Group II: Education + decision support to provide suggestions for care optimization Active Control 1 Intervention

Group III: Education + facilitated referral to cardiometabolic team-based center for care optimization Active Control 1 Intervention

Who Is Running the Clinical Trial?

American College of Cardiology

Lead Sponsor

Trials

18

Recruited

312,000+

Novo Nordisk A/S

Industry Sponsor

Trials

1,578

Recruited

3,813,000+

Lars Fruergaard Jørgensen

Novo Nordisk A/S

Chief Executive Officer since 2017

MSc in Finance and Business Administration, Aarhus School of Business, Aarhus University, Denmark

Martin Holst Lange

Novo Nordisk A/S

Chief Medical Officer since 2021

MD from University of Copenhagen